Pembrolizumab coformulated with hyaluronidase alfa (MK-3475A)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Pembrolizumab coformulated with hyaluronidase alfa (MK-3475A), covering 2026-04-08 to 2026-04-08. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) [Phase 2]